pNET G3 Tumor Stabilization Achieved by an Individualized Molecular Therapy Based on Tumor Genome Sequencing Results Abstract #2239

Introduction: High-grade pancreatic neuroendocrine neoplasms (pNENs) constitute a heterogeneous group of malignant neoplasms, encompassing neuroendocrine tumors (NET) G3 and carcinomas (NEC). Due to poor data on NET G3 tumors no standard therapy in metastatic disease could be established so far. Tumor genome sequencing might help to better profile NET G3 tumors and could provide novel opportunities for individualized and thereby successful patient specific treatments.
Aim(s): -
Materials and methods: -
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Case reports
Presenting Author: Martina Steurer

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2694 The Incidence of Gastrointestinal Neuroendocrine Tumors in the Russian Population
Introduction: Over the past four decades, the incidence of neuroendocrine tumors (NETs) has increased. The limited choice of treatments, broad clinical variability of the syndrome explains the increased interest in NETs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Alina Isiangulova
#2739 Epigenetic Landscape of Pancreatic Neuro-Endocrine Tumors Reveals Distinct Cells of Origin and Means of Tumor Progression
Introduction: Pancreatic Neuroendocrine Tumors (PanNETs) arise from cells of the Islets of Langerhans. The majority of PanNETs are non-functional and their cell of origin cannot be defined analysing specific hormone production. Cell of origin assessment has proven importance to identify risk factors, prevent tumour development, and tailor treatment in many malignancies. Recent data on super-enhancer signatures has suggested a potential origin of PanNET from α- or β-cells. We and others have shown that distinct epigenetic profiles assessed by DNA methylation (DNAme) characterize genomic and prognostic groups of PanNET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Annunziata Di Domenico
#2769 Treatment Outcomes of Patients with G3 Neuroendocrine Neoplasms
Introduction: Extra-pulmonary neuroendocrine carcinomas (NEC) and neuroendocrine tumors (NET) G3 are aggressive neoplasia associated with a limited prognosis.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Josephine Schenk
#2781 Case Report: Whole Exon Sequencing of Primary Lesion and Metastatic Liver Lesion in Pancreatic Neuroendocrine Tumor
Introduction: Pancreatic neuroendocrine neoplasms(NENs) are classified into neuroendocrine tumors (NET) G1, G2, G3, and neuroendocrine carcinoma (NEC), which are different pathogenesis. The two kinds of tumors that occurs in the same lesion in one patient is very rare. We found high grade neuroendocrine neoplasms(NENG3) with a diameter of 0.1 cm in a patient with a pancreatic NETG2 (1.7 cm in diameter). The cells were significant atypia with Ki67 index of 60%, focal necrosis, while metastatic nodules in the liver (12, 0.1-1.1 cm in diameter) were all high grade NENG3.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Yanfen Shi
Authors: Shi Y, Zhong D, Li Y, Niu Y, ...
#2786 Outcome of NET Liver Metastases Treated by TAE Using Microspheres
Introduction: Liver metastases are common in patients with neuroendocrine tumors (NETs), which are associated with the prognosis. Transarterial embolization (TAE) is one of the options for selective therapy in patients with multiple unresectable progressive liver metastases after chemotherapy.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Xiaoliang Chen
Authors: Chen X, Hu L, ...